Thus, those cancer cells with extremely high levels of SLC2A1, such as those hypermethylated at DERL3, will be very sensitive to drugs that downregulate SLC2A1 expression, such as direct (shikonin) or indirect (AKT inhibitor VIII) PKM2 inhibitors. Here, SLC2A1 is linked to cancer.